-
-
-
-
-
-
-
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
-
-
-
-
-
-
-
KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
-
-
-
-
-
-
-
KemPharm Receives Day-74 Letter for KP415 NDA
-
-
-
-
-
-
-
KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
-
-
-
-
-
-
-
Kempharm (KMPH) PT Lowered to $14 at RBC Following FDA Panel Vote
-
-
-
-
-
-
-
KemPharm (KMPH) Announces FDA Committee Meeting Date to Review KP201/APAP NDA
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

